Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

University of California, Berkeley

http://www.berkeley.edu/

Latest From University of California, Berkeley

Sanofi ThiNKs Scribe’s CRISPR Approach Can Advance Its NK Cell Therapy Goals

Deal Snapshot: CRISPR-Cas9 co-inventor Jennifer Doudna-founded gene-editing firm inks its second large collaboration, teaming with Sanofi on off-the-shelf natural killer cell therapies for cancer.

Deals Business Strategies

Tech Transfer Roundup: Erasca Calls On MD Anderson To Advance Its RAS/MAPK Pipeline

Plus agreements involving Hansoh/GHDDI, BriaCell/UMBC, Novartis/UC Berkeley, NeoPhore/Memorial Sloan Kettering, GEn1E/UM-Baltimore, ValoTx/University of Helsinki and Sosei/Cancer Research UK.

Tech Transfer Round-Up Deals

Tech Transfer Roundup: Amylyx Goes Pipeline Hunting While Seeking US Approval Of ALS Candidate

Amylyx is funding research at the Sunnybrook Research Institute to investigate Bax and Bak inhibition in neurodegenerative disease. Repertoire looks into HPV+ cancer with Memorial Sloan Kettering.

Tech Transfer Round-Up Deals

Deal Watch: Amgen Taps Plexium's Expertise In Targeted Protein Degradation

Mersana will help J&J develop antibody-drug conjugates against three targets, while AstraZeneca out-licenses a candidate for peripheral artery disease to Regio.

Deal Watch Business Strategies
See All

Company Information

  • Industry
  • Academic and Research Institutions
UsernamePublicRestriction

Register